Cannabis company Elixinol Global announces supply agreement with Pet Releaf

The Elixinol Global Ltd (ASX:EXL) share price could be on the move on Thursday after announcing a new supply agreement…

| More on:
A jar of medicinal cannabis buds and a few buds on a table

Image Source: Getty Images

The Elixinol Global Ltd (ASX: EXL) share price could push higher today following the release of an announcement out of the medicinal cannabis company this morning.

What did Elixinol Global announce?

This morning Elixinol Global announced that its wholly-owned subsidiary, Elixinol LLC, has entered into a manufacturing and supply agreement with Pet Releaf in the United States.

According to the release, Pet Releaf is the pioneer and market leading brand for hemp-derived cannabidiol (CBD) oils, topicals, and treats for pets.

Its products are currently sold online and in over 4,000 independent pet stores across the USA and globally.

The release explains that Elixinol has exclusively produced and supplied CBD extract sourced from USDA Organic certified hemp strains grown specifically for Pet Releaf since its inception in 2014. In April 2019, Elixinol acquired a 25% equity interest in Pet Releaf.

Today’s agreement is for an initial 18-month term which can be renewed annually for multiple years. It will see Pet Releaf purchase a minimum US$18 million (approximately A$26.8 million) worth of products over the term and pay a deposit of US$1.8 million (approximately A$2.7 million) by way of three equal payments during the term of the agreement.

Elixinol Global’s chief executive officer, Stratos Karousos, was pleased with the agreement.

He said: “This exclusive agreement with Pet Releaf further strengthens our relationship and ensures Pet Releaf’s products will have scalability and ongoing quality of supply. The agreement is consistent with Elixinol’s growth strategy, increasing distribution of our branded products through partnerships with trusted and highly regarded brands.”

This sentiment was echoed by the company’s chief technology officer, Gabriel Ettenson.

He said: “This agreement reflects Elixinol’s commitment to continue to build on the excellent relationship that both companies have enjoyed over many years and leverage seed to sale supply chain efficiencies with extensive scalability, in-house scientific expertise and proprietary processing technologies.”

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News